Heart failure & cardiomyopathiesSecondary analysis
Dipstick proteinuria and outcomes in patients with heart failure and reduced ejection fraction: insights from GALACTIC-HF
- Secondary analysis of the GALACTIC-HF randomised trial
- retrospective analysis
Authors' conclusion
In GALACTIC-HF, higher DP levels were independently associated with increased risk of adverse clinical outcomes in patients with reduced ejection fraction.
Study context
- Population
- Patients with HFrEF in GALACTIC-HF (omecamtiv mecarbil vs placebo) with baseline dipstick proteinuria databaseline dipstick proteinuria (DP) data available
- Participants
- 7,790 patients
- Comparison
- Dipstick proteinuria levels
- Negative/tracen = 5,910reference
- 1+n = 995
- ≥2+n = 885
- Primary endpoint
- First HF event (hospitalization or urgent visit for HF) or CV death
Primary result
As reported in the abstract
Primary outcome incidence rate (per 100 person-years)
Secondary outcomes
Heart failure (HF) event, CV death, all-cause mortality
- Similar trends for components of primary outcome and all-cause mortality
Association of DP with outcomes, by eGFR (subgroup)
- Association stronger with preserved eGFR (≥60 ml/min/1.73 m²) than reduced eGFR (<60 ml/min/1.73 m²)
Original publication
Dipstick proteinuria and outcomes in patients with heart failure and reduced ejection fraction: insights from GALACTIC-HF. Eur J Heart Fail. Published 13 January 2026. doi:10.1093/ejhf/xuag003
Summarised from the published abstract; every number is checked against it